Godlewski Adrian, Mojsak Patrycja, Pienkowski Tomasz, Lyson Tomasz, Mariak Zenon, Reszec Joanna, Kaminski Karol, Moniuszko Marcin, Kretowski Adam, Ciborowski Michal
Clinical Research Centre, Medical University of Bialystok, Bialystok, 15-276, Poland.
Department of Neurosurgery, Medical University of Bialystok, Bialystok, 15-276, Poland.
Metabolomics. 2025 Feb 22;21(2):33. doi: 10.1007/s11306-025-02231-5.
Extracranial and intracranial tumors are a diverse group of malignant and benign neoplasms, influenced by multiple factors. Given the complex nature of these tumors and usually late or accidental diagnosis, minimally invasive, rapid, early, and accurate diagnostic methods are urgently required. Metabolomics offers promising insights into central nervous system tumors by uncovering distinctive metabolic changes linked to tumor development.
This study aimed to elucidate the role of altered metabolites and the associated biological pathways implicated in the development of gliomas and meningiomas.
The study was conducted on 95 patients with gliomas, 68 patients with meningiomas, and 71 subjects as a control group. The metabolic profiling of gliomas and meningiomas achieved by integrating untargeted metabolomic analysis based on GC-MS and targeted analysis performed using LC-MS/MS represents the first comprehensive study. Three comparisons (gliomas or meningiomas vs. controls as well as gliomas vs. meningiomas) were performed to reveal statistically significant metabolites.
Comparative analysis revealed 97, 56, and 27 significant metabolites for gliomas vs. controls, meningiomas vs. controls and gliomas vs. meningiomas comparison, respectively. Moreover, among above mentioned comparisons unique metabolites involved in arginine biosynthesis and metabolism, the Krebs cycle, and lysine degradation pathways were found. Notably, 2-aminoadipic acid has been identified as a metabolite that can be used in distinguishing two tumor types.
Our results provide a deeper understanding of the metabolic changes associated with brain tumor development and progression.
颅外和颅内肿瘤是一组受多种因素影响的恶性和良性肿瘤。鉴于这些肿瘤的复杂性以及通常较晚或偶然的诊断情况，迫切需要微创、快速、早期且准确的诊断方法。代谢组学通过揭示与肿瘤发展相关的独特代谢变化，为中枢神经系统肿瘤提供了有前景的见解。
本研究旨在阐明代谢物改变以及相关生物途径在神经胶质瘤和脑膜瘤发展中的作用。
该研究对95例神经胶质瘤患者、68例脑膜瘤患者和71名作为对照组的受试者进行。通过整合基于气相色谱 - 质谱联用（GC-MS）的非靶向代谢组学分析和使用液相色谱 - 串联质谱（LC-MS/MS）进行的靶向分析来实现神经胶质瘤和脑膜瘤的代谢谱分析，这是第一项全面研究。进行了三项比较（神经胶质瘤或脑膜瘤与对照组以及神经胶质瘤与脑膜瘤之间）以揭示具有统计学意义的代谢物。
比较分析分别揭示了神经胶质瘤与对照组、脑膜瘤与对照组以及神经胶质瘤与脑膜瘤比较中的97种、56种和27种显著代谢物。此外，在上述比较中发现了参与精氨酸生物合成与代谢、三羧酸循环和赖氨酸降解途径的独特代谢物。值得注意的是，2-氨基己二酸已被确定为可用于区分两种肿瘤类型的代谢物。
我们的结果为与脑肿瘤发展和进展相关的代谢变化提供了更深入的理解。
